What is the Krsnaa Diagnostics PE ratio today?
Krsnaa Diagnostics' PE ratio is 16.6 at the 29 October 2026 close (₹497.95 a share): a market capitalisation of ₹1,615 crore divided by consolidated net profit of ₹97.5 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹101 crore) it is 15.9.
What is the Krsnaa Diagnostics debt to equity ratio?
Krsnaa Diagnostics' debt-to-equity ratio was 0.55 on 31 March 2026: borrowings of ₹534 crore against total equity of ₹980 crore. A year earlier, on 31 March 2025, it was 0.23.
What is the Krsnaa Diagnostics net worth?
Krsnaa Diagnostics' net worth — shareholders' equity in its consolidated balance sheet — was ₹980 crore on 31 March 2026, up 11.1% from ₹883 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,615 crore at the 29 October 2026 close.
What is the Krsnaa Diagnostics PB ratio (price to book value)?
Krsnaa Diagnostics' price-to-book (PB) ratio is 1.65 at the 29 October 2026 close: a market capitalisation of ₹1,615 crore divided by shareholders' equity (book value) of ₹980 crore on 31 March 2026. That is a book value of ₹302.23 per share against a share price of ₹497.95.
What is the Krsnaa Diagnostics ROE and ROCE?
In FY26, Krsnaa Diagnostics' return on equity (ROE) was 10.9% and its return on capital employed (ROCE) was 9.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 9.2% and ROCE 10.9%.
What is the Krsnaa Diagnostics book value per share?
Krsnaa Diagnostics' book value per share was ₹302.23 on 31 March 2026: shareholders' equity of ₹980 crore divided by the 3.24 crore shares in issue, up 10.6% from ₹273.39 a year earlier. The share price at the 29 October 2026 close was ₹497.95.
What is the Krsnaa Diagnostics market cap?
Krsnaa Diagnostics' market capitalisation was ₹1,615 crore at the 29 October 2026 close: 3.24 crore shares at ₹497.95 each.
Is Krsnaa Diagnostics debt free?
No. Krsnaa Diagnostics had borrowings of ₹534 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.55. Its cash and current investments were ₹361 crore, so its net debt was ₹174 crore.
What is the Krsnaa Diagnostics dividend in 2026 and its record date?
In 2026, Krsnaa Diagnostics has declared one dividend: ₹2 with record date 18 September 2026.
What is the Krsnaa Diagnostics EPS?
Krsnaa Diagnostics' basic earnings per share (EPS) were ₹31.30 in FY26, against ₹24.04 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹30.06.
What is the Krsnaa Diagnostics dividend yield?
Krsnaa Diagnostics' dividend yield is 0.40% at the 29 October 2026 close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹497.95. They were ₹2 on 18 September 2026.
When are the Krsnaa Diagnostics next results?
Krsnaa Diagnostics will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
What is the Krsnaa Diagnostics promoter holding?
Promoters held 27.11% of Krsnaa Diagnostics on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Krsnaa Diagnostics free cash flow?
In FY26, Krsnaa Diagnostics generated ₹143 crore of cash from operations and spent ₹219 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹76.2 crore. In FY25 it was −₹39.3 crore.
What are the Krsnaa Diagnostics latest quarterly results?
Krsnaa Diagnostics' latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹16.6 crore, down 19.3% from ₹20.5 crore in Q1 FY26; revenue from operations ₹236 crore, up 22.1% year on year.
What is the Krsnaa Diagnostics shareholding pattern?
On 30 September 2026, Krsnaa Diagnostics' shares were held by promoters 27.11%, foreign portfolio investors (FII/FPI) 3.84%, domestic institutions (DII) 14.50% (including mutual funds at 10.17%) and retail and other non-institutional investors 54.54%. Over the year, FII holding was up 0.17 percentage points from 3.67% and DII holding was down 0.46 percentage points from 14.96%.
What is the Krsnaa Diagnostics revenue and profit in FY26?
In FY26 (April 2025–March 2026), Krsnaa Diagnostics' consolidated net profit was ₹101 crore, up 30.7% from ₹77.6 crore in FY25, on revenue from operations of ₹773 crore (up 7.8%). Over three years, from FY23, net profit was up 63.3%.
How does the Krsnaa Diagnostics PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Krsnaa Diagnostics' PE ratio is 15.9, the lowest of the four: Suraksha Diagnostic 51.7, Health X Platform 755.3 and Nephrocare Health Services 82.1, a peer average of 296.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
How does Krsnaa Diagnostics compare with its peers?
On FY26 consolidated figures, against Suraksha Diagnostic, Health X Platform and Nephrocare Health Services: Krsnaa Diagnostics' operating margin of 15.7% is the second highest of the four (Suraksha Diagnostic 17.4%, Health X Platform −4.5%, Nephrocare Health Services 13.7%; peer average 8.9%); its return on equity of 10.9% is the second highest of the four (Suraksha Diagnostic 14.1%, Health X Platform 0.2%, Nephrocare Health Services 6.9%; peer average 7.1%).
Krsnaa Diagnostics vs Suraksha Diagnostic: how do they compare?
In FY26, Krsnaa Diagnostics earned net profit of ₹101 crore on revenue of ₹773 crore, against ₹32.2 crore on ₹310 crore for Suraksha Diagnostic. Krsnaa Diagnostics' operating margin was 15.7% (Suraksha Diagnostic 17.4%) and its return on equity 10.9% (Suraksha Diagnostic 14.1%). At the 29 October 2026 close, Krsnaa Diagnostics' market capitalisation was ₹1,615 crore against ₹1,664 crore for Suraksha Diagnostic, and its PE ratio on FY26 profit 15.9 against 51.7.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
